SYNLAB AG

  • WKN: A2TSL7
  • ISIN: DE000A2TSL71
  • Land: Deutschland

Nachricht vom 26.05.2021 | 07:30

SYNLAB and Hospital District of Helsinki and Uusimaa extend partnership for comprehensive PCR-testing for SARS-CoV-2 in Finland

DGAP-News: SYNLAB AG / Key word(s): Contract
26.05.2021 / 07:30
The issuer is solely responsible for the content of this announcement.

SYNLAB and Hospital District of Helsinki and Uusimaa extend partnership for comprehensive PCR-testing for SARS-CoV-2 in Finland

- SYNLAB and Hospital District of Helsinki and Uusimaa renew contract for comprehensive PCR-testing on SARS-CoV-2 in Finland

- SYNLAB will analyse and evaluate an estimated 5,000 - 20,000 PCR-tests per day, with SYNLAB's Helsinki laboratory functioning as central hub laboratory

- New contract will apply from August 2021 for a minimum of 7 months and run up to December 2023

- Total revenue from the contract is estimated around EUR 50 million per year, with a minimum of around EUR 35 million

SYNLAB, Europe's leading medical diagnostics services provider, and Hospital District of Helsinki and Uusimaa (HUS), Finland's largest medical care specialist, announce the renewal of their successful partnership for comprehensive PCR-testing for SARS-CoV-2 in Finland, as a result of a public tender process. The cooperation will strengthen the capabilities of the Finnish healthcare system in the COVID- 19 response, and it will further increase protection for the Finnish people.

In close collaboration, SYNLAB and HUS will analyse about 5,000 - 20,000 PCR-tests per day from individuals sampled all over Finland. The analysis and evaluation of the tests will be carried out on a 24/7 basis at SYNLAB's Helsinki laboratory, which is already playing a central role in the SARS-CoV-2 pandemic response in Finland. Patients will receive their test results securely, quickly, and conveniently within 12 - 24 hours.

This contract is an extension of the previous partnership initiated in April 2020. It will start in August 2021 for a minimum of 7 months and run up to December 2023.
Depending on the ultimate test volume, total revenue from the contract is estimated around EUR 50 million per year, with a minimum of around EUR 35 million.

"We are grateful to continue our close collaboration with HUS. We will spare no effort to support the Finnish healthcare system both in the COVID-19 response and "back to normal" phase. Building up on SYNLAB's strong commitment to medical excellence and customer centricity, we will provide state-of-the-art medical diagnostic services that are focused on patients and their needs," says Mathieu Floreani, CEO of SYNLAB.

Aarne Aktan, CEO of SYNLAB Finland, underlines SYNLAB's commitment to complement the Finnish healthcare system and says: "We look forward to continuing our successful and trusted collaboration with Finland's largest hospital network. Based on our local experienced medical teams and network of SARS-CoV-2 testing services, we will deliver rapid results to patients using advanced technology in our laboratory in Helsinki."

Lasse Lehtonen, Director of Diagnostic services in HUS, sees the continuation of the collaboration being positive for both parties. "We have been happy with SYNLAB's testing capability so far and we are looking forward in continuing the cooperation. This agreement enables fast, secure and scalable SARS-CoV-2 testing services for us - with enough capacity to fulfil the needs of our region as well as our nationwide border controlling."

- End -

For more information:

Media contact:
Florian Brueckner, FTI Consulting
+49 (0) 160 9192 5265
Florian.Brueckner@fticonsulting.com
Investor contact:
Mark Reinhard, SYNLAB
+49 (0) 170 118 3753
Mark.Reinhard@synlab.com



About SYNLAB

- SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic services company and offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.

- Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of patients and customers.

- SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. Around 20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB carries out ~500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020.

- More information can be found on www.synlab.com



26.05.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Interview im Fokus

„Eine Investition in Mutares lohnt sich“

Mutares ist ein europaweit führender Private-Equity-Investor, der sich auf Sondersituationen wie Abspaltungen von großen Konzernen oder Turnaround- und Nachfolgesituationen spezialisiert hat. Ziel ist es, mit den Investments einen Return auf das eingesetzte Kapital von 7 bis 10 zu erzielen. Mit der jüngsten Mittelfristprognose hat der Münchner Finanzinvestor auf Basis von 5 Mrd. Euro Konzernumsatz eine Nettorendite für die börsennotierte Holding von 1,8 bis 2,2 % in Aussicht gestellt. In der Mitte der Zielspanne wird somit ein Nettogewinn von circa 100 Mio. Euro anvisiert. Hauck & Aufhäuser hat in der jüngsten Analyse ein Buy-Rating mit Kursziel für Mutares von 37,50 Euro ausgegeben.

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

23. September 2021